Kids v Cancer launches Compassionate Use Navigator tools

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

KIDS V CANCER launched the Compassionate Use Navigator for the pediatric oncology community that provides up-to-date information on the compassionate use application process.

The Compassionate Use Navigator provides: an option for physicians to request help from Compassionate Use Navigator staff in completing a compassionate use application; step-by-step instructions on how to apply for compassionate use, including forms and templates; assistance in identifying points of contact at drug companies; and information on FDA and IRB rules for obtaining compassionate use medications.

In addition, the navigator aims to fill knowledge gaps about compassionate use by collecting data on the numbers and outcomes of applications. This data will lay the groundwork for developing next steps to improve access to drugs for those in dire need.

Table of Contents

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login